Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know

Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell therapies. For the good part of 2019-2020, the stock found an equilibrium price between $0.20-$0.28 respectively.

Table of Contents 
1. Introduction 
2. ATNM forecasts and analysis 
3. YIG's take on ATNM and its future

ATNM forecasts and stock analysis

With a current market cap of $177.70 million and a 5 Year Beta of 1.54, ATNM has cemented itself as a fair performing Bio-Pharma trading on the NYSE. The stock recently earned itself #2 on Zacks Rank, sparking a surge in investor interest. What’s Zacks Rank?

“In 1978, Zacks’ Founder and CEO hit upon a key discovery: earnings estimate revisions are the most powerful force impacting stock prices. With this crucial finding, he developed the Zacks Rank to harness the power of earnings estimates.

For more than a quarter century, it has more than doubled the S&P 500 with an average gain of +24.04% per year. These returns cover a period from January 1, 1988 through June 1, 2020.”

Zacks Rank official website, read more here.

Although an impressive feat, it is worthwhile mentioning forecasts and predictions are far from a sure thing. Further, the forecasts published on the Wallstreet Journal have concluded an average price target at $2.83 with a low targeted at $1.50. These price targets are extremely bullish and suggest ATNM to capitalise on strong growth. With such positive targets, it is important to remember the current market environment. With a global pandemic worsening as time has progressed, it would be vital to calculate this in your investment decision (opinion not advice).

YIG’s breakdown on Actinium Pharmaceuticals and its future

Before I begin, I am obliged to remind our viewers that this is not financial advice but rather commentary from extensive research. 

Short answer: YIG believes ATNM holds strong potential, however the current market environment remains investors greatest threat 

The strong forecasts and recent investor momentum are encouraging signs for long term shareholders. With price targets extremely bullish, it is likely ATNM will continue the strong momentum for the better part of this week (opinion). From what we know, when a stock picks up momentum, the change of investor sentiment shifts. So here is the short term risk. As speculators look to make a quick buck – the stock becomes more and more volatile.

Let’s take the technical analysis out of the equation. Any investment in this current market environment exposes that investor to the risks of the pandemic and the up-coming election. This exposure is often looked past in certain price targets released by major investment firms. Hence why they continue to update their positions.

It is important to understand the general market sentiment for any stock you invest in. For example, we see intense “pump and dumps” in the current COVID-19 vaccine industry. YIG have analysed these market movements and concluded the Bio-Pharma industry to be one of the most volatile trading industries on the US stock market today. In the defence of ATNM, the stock is not directly related to COVID-19 speculation in any way, shape or form. Therefore, we can conclude that the strong surge in momentum looks positive for the bone marrow pioneer Actinium Pharmaceuticals.

The information above should not be taken as financial advice. Youth Investment Group has no liability for personal financial interests or investment decisions. You should make your own investment decisions based upon your own research and what you believe is best for you.